D.A. Davidson & Co’s Amedisys AMED Stock Holding History

D.A. Davidson & Co’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,518	Closed	-$262K	–	1284
2022 Q1	$262K	Buy	+1,518	New	+$227K	﹤0.01%	1125

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

D.A. Davidson & Co's AMED Position: Q2 2022 in Review

D.A. Davidson & Co sold out of Amedisys (AMED) in Q2 2022, closing a stake of 1,518 shares — an estimated $262K sold.

D.A. Davidson & Co first reported a position in AMED in Q1 2022 and held it in 1 quarter. The position peaked at $262K in Q1 2022. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

D.A. Davidson & Co reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
D.A. Davidson & Co sold 1,518 Amedisys shares in Q2 2022, an estimated $262K.
D.A. Davidson & Co first reported a position in Amedisys in Q1 2022 and held it in 1 quarter.
D.A. Davidson & Co's Amedisys position peaked at $262K in Q1 2022.
288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on D.A. Davidson & Co's 13F filing for Q2 2022, filed 28 Jul 2022.